Short-term treatment with the drug ruxolitinib prevents B-cell acute lymphoblastic leukaemia (B-ALL) in mice that have a genetic predisposition to the disease. St. Jude Children’s Research Hospital and the Cancer Research Center in Salamanca, Spain, led the research. The findings appear in Cancer Research.
The work provides the first evidence in an animal of a possible strategy to prevent B-ALL. Leukaemia is the most common childhood cancer and the leading cause of paediatric cancer deaths.
“I realise these are early days, but I cannot help getting excited about the findings,” said Kim Nichols, M.D., director of the St. Jude Cancer Predisposition Division. “This is the first kernel of hope for a medical intervention to prevent hereditary forms of leukaemia or other hereditary cancers in general.”
Nichols and Isidro Sánchez-García, Ph.D., of the Cancer Research Center (CSIC-IBMCC) are corresponding authors of the study. The other senior authors include Carolina Vicente-Dueñas, Ph.D., of Institute of Biomedical Research of Salamanca (IBSAL).
About 5% of children with B-ALL develop the disease due to an underlying genetic predisposition. In these children, abnormal premalignant cells may exist in the bone marrow. While many of these children do not develop leukaemia, some do. Currently, there is no method to identify children at greatest risk and prevent their disease.
The study focused on B-ALL that arises when children carry one altered and one normal copy of the PAX5 gene. The PAX5 gene encodes a protein that is essential for normal development of immune cells known as B-lymphocytes. PAX5 mutations are among the least common of the germline mutations associated with B-ALL.
Like children with PAX5 mutations, previous research from Sánchez-García showed that B-ALL develops in a proportion of mice that carry one altered copy of the Pax5 gene, but only when mice are exposed to immune stress such as an infection. He also showed that the immature B-lymphocytes in these mice are particularly dependent on the cytokine interleukin-7 (IL-7) for their survival. Blocking IL-7 signalling using the drug ruxolitnib led to increased cell death in the laboratory.
The targeted therapy
Based on this earlier finding, PAX5-mutant mice in this study were treated with ruxolitinib for one month after they were moved from a germ-free facility to one in which they were exposed to common mouse pathogens.
The change marked the models’ first exposure to infections. Remarkably, only one of the 29 mice who received ruxolitinib later developed B-ALL. In contrast, eight of the 34 mutant mice who were not treated with the drug later developed B-ALL.
The U.S. Food and Drug Administration has approved ruxolitinib for the treatment of several paediatric and adult disorders.
The drug inhibits cell signalling molecules called cytokines, including IL-7. In this study, researchers hypothesize that ruxolitinib worked by inhibiting IL-7 and eliminating the premalignant blood cells before they had a chance to acquire secondary mutations that triggered their transformation to full-blown leukaemic cells.
“More research is needed to better understand PAX5 B-ALL and how treatment with ruxolitinib works,” Nichols said. One important future step is determining how long children with the inherited PAX5 mutation would need ruxolitinib treatment to prevent B-ALL.
Researchers also want to explore a similar approach to prevent other hereditary cancers, including other B-ALL subtypes that feature pre-malignant cells.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.